 SAN DIEGO, Sept. 09, 2021 GLOBE NEWSWIRE -- Metacrine, Inc. NASDAQ:MTCR, a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today announced that it has completed enrollment for its Phase 2a trial evaluating MET642, an optimized farnesoid X receptor FXR agonist, in patients with non-alcoholic steatohepatitis NASH. The Company plans to report interim data from the first 60 patients early in the fourth quarter of 2021. 